Zevra Therapeutics Inc [ZVRA] stock prices are up 1.26% to $11.25 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ZVRA shares have gain 4.07% over the last week, with a monthly amount glided 15.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zevra Therapeutics Inc [NASDAQ: ZVRA] stock has seen the most recent analyst activity on July 02, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $26. On October 07, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $20 on the stock. Maxim Group reiterated its Buy rating and increased its price target to $25 on September 24, 2024. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $17 as its price target on September 24, 2024. Maxim Group reiterated a Buy rating for this stock on April 02, 2024, and upped its price target to $18. In a note dated March 12, 2024, William Blair initiated an Outperform rating.
The stock price of Zevra Therapeutics Inc [ZVRA] has been fluctuating between $6.19 and $13.16 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $11.25 at the most recent close of the market. An investor can expect a potential return of 77.78% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
The Zevra Therapeutics Inc [NASDAQ:ZVRA] reported sales of 40.59M for trailing twelve months, representing a surge of 495.65%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -1.77%, Pretax Profit Margin comes in at -1.86%, and Net Profit Margin reading is -2.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -2.01 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Zevra Therapeutics Inc [NASDAQ:ZVRA]’s Current Ratio is 3.02. On the other hand, the Quick Ratio is 2.93, and the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 15.16, the price to book ratio is 15.00.
Transactions by insiders
Recent insider trading involved Thompson Rahsaan, Chief Legal & Compliance, that happened on Jun 26 ’25 when 24000.0 shares were sold. Officer, RAHSAAN THOMPSON completed a deal on Jun 26 ’25 to buy 24000.0 shares. Meanwhile, Director Watton Corey Michael bought 300.0 shares on Mar 28 ’25.
